Literature DB >> 30190999

Systemic chemotherapy with oxaliplatin is a good option for advanced hepatocellular carcinoma.

Shukui Qin1,1, Qiong Wu2,2.   

Abstract

Entities:  

Keywords:  hepatocellular carcinoma; oxaliplatin; systemic chemotherapy; treatment

Year:  2015        PMID： 30190999      PMCID： PMC6095414          DOI： 10.2217/hep.15.14

Source DB:  PubMed          Journal:  Hepat Oncol        ISSN： 2045-0923


× No keyword cloud information.
  10 in total

Review 1.  Oxaliplatin-based chemotherapy: a new option in advanced hepatocellular carcinoma. a systematic review and pooled analysis.

Authors:  F Petrelli; A Coinu; K Borgonovo; M Cabiddu; M Ghilardi; V Lonati; S Barni
Journal:  Clin Oncol (R Coll Radiol)       Date:  2014-05-21       Impact factor: 4.126

2.  Systemic therapy for hepatocellular carcinoma.

Authors:  James J Harding; Ghassan K Abou-Alfa
Journal:  Chin Clin Oncol       Date:  2013-12

3.  Drug development for hepatocellular carcinoma: knowing the past helps to understand the future.

Authors:  Stephen L Chan
Journal:  Oncologist       Date:  2014-09-15

4.  Oxaliplatin: a review in the era of molecularly targeted therapy.

Authors:  T Alcindor; N Beauger
Journal:  Curr Oncol       Date:  2011-01       Impact factor: 3.677

5.  Global cancer statistics, 2012.

Authors:  Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-02-04       Impact factor: 508.702

6.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk Kim; Rongcheng Luo; Jifeng Feng; Shenglong Ye; Tsai-Sheng Yang; Jianming Xu; Yan Sun; Houjie Liang; Jiwei Liu; Jiejun Wang; Won Young Tak; Hongming Pan; Karin Burock; Jessie Zou; Dimitris Voliotis; Zhongzhen Guan
Journal:  Lancet Oncol       Date:  2008-12-16       Impact factor: 41.316

7.  Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study.

Authors:  Aziz Zaanan; Nicolas Williet; Mohamed Hebbar; Tienhan Sandrine Dabakuyo; Laetitia Fartoux; Touraj Mansourbakht; Olivier Dubreuil; Olivier Rosmorduc; Stéphane Cattan; Franck Bonnetain; Valérie Boige; Julien Taïeb
Journal:  J Hepatol       Date:  2012-09-16       Impact factor: 25.083

8.  Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.

Authors:  Shukui Qin; Yuxian Bai; Ho Yeong Lim; Sumitra Thongprasert; Yee Chao; Jia Fan; Tsai-Shen Yang; Vajarabhongsa Bhudhisawasdi; Won Ki Kang; Yu Zhou; Jee Hyun Lee; Yan Sun
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

9.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

10.  Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study.

Authors:  Shukui Qin; Ying Cheng; Jun Liang; Lin Shen; Yuxian Bai; Jianfeng Li; Jia Fan; Lijian Liang; Yaqi Zhang; Gang Wu; Kun-Ming Rau; Tsai-Shen Yang; Zhixiang Jian; Houjie Liang; Yan Sun
Journal:  Oncologist       Date:  2014-09-15
  10 in total
  2 in total

Review 1.  Antibody-drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance.

Authors:  A R Kumar; M Murali; B Nair; K Pavithran; A R Devan; G K Pradeep; L R Nath
Journal:  Clin Transl Oncol       Date:  2021-09-30       Impact factor: 3.405

2.  Upregulated UCA1 contributes to oxaliplatin resistance of hepatocellular carcinoma through inhibition of miR-138-5p and activation of AKT/mTOR signaling pathway.

Authors:  Guolin Huang; Li Li; Chaoyong Liang; Fei Yu; Cuifang Teng; Yingxing Pang; Tongtong Wei; Jinjing Song; Hanlin Wang; Xiaoli Liao; Yongqiang Li; Jie Yang
Journal:  Pharmacol Res Perspect       Date:  2021-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.